Table 3 Metabolic effects of APP for schizophrenia reported in included reviews
From: Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Review ID | Outcome measure | Findings reported | Interpretation |
|---|---|---|---|
Metabolic syndrome | |||
 Gallego 2012 [33] | Metabolic syndrome | No synthesis or conclusion reported for this outcome | Not applicable (comparison not specified) |
 Young 2015 [25] | Proportion with Metabolic syndrome in APP users | No synthesis or data reported. | They report that there is an association between metabolic syndrome and APP but no data reported. |
Lipid profile outcomes | |||
 Galling 2016 [32] | Mean Total cholesterol mg/dl | SMD −0.27 (95%CI -0.43, −0.10) | APP was associated with lower total and LDL cholesterol compared to monotherapy |
Mean LDL mg/dl | SMD −0.28 (95%CI -0.45, − 0.11) | ||
 Canadian Agency for Drugs and Technologies in Health 2012 [35] | Mean Total cholesterol | Total cholesterol statistically significantly lower with Clozapine +AP | Adding a second antipsychotic to clozapine was associated with lower total and LDL cholesterol compared to monotherapy with clozapine. |
Mean LDL | LDL statistically significantly lower with Clozapine +AP | ||
 Tracy, 2013 [27] | NR | Aripiprazole co-treatment reregulates lipid profiles | APP including aripiprazole is associated with good lipid profile (comparison not specified) |
 Srisurapanont, 2015 [28] | Mean LDL mg/dl | MD −11.06 (95%CI -18.25, −3.87) | Aripiprazole + clozapine APP was associated with lower total and LDL cholesterol compared to monotherapy with clozapine |
 Mizuno, 2014 [29] | Mean Total cholesterol mg/dl | MD −12.81 (95%CI -19.35, −6.27) | |
Mean LDL mg/dl | MD − 11.69 (95% CI -19.12, −4.26 | ||
 Gallego, 2012 [33] | NR | Aripiprazole augmentation was associated with a decrease in dyslipidaemia | APP with aripiprazole is associated with good lipid profile (comparison not specified) |
 Correll, 2013 [34] | Mean Total cholesterol | SMD −0.4 (95% CI -0.7,-0.2) | APP with aripiprazole was associated with lower triglycerides, and total and LDL cholesterol but not HDL cholesterol, compared to clozapine or olanzapine monotherapy |
Mean LDL | SMD −0.3 (CI -0.6,- 0.1) | ||
Mean triglycerides | SMD −0.4 (CI -0.7,- 0.0) | ||
HDL level | Mean NR; p = 0.95 | ||
Glucose profile outcomes | |||
 Mizuno, 2014 [29] | Mean HbA1C | MD −0.65 (95%CI -1.25, − 0.06) | APP with aripiprazole is associated with lower HbA1C levels than AP monotherapy |
 Correll, 2013 [34] | Decrease in glucose levels | Mean NR; p = 0.41 | APP with aripiprazole was associated with no significant change in glucose levels compared to clozapine or olanzapine monotherapy |
 Gallego, 2012 [33] | NR | No synthesis or data reported. | APP has been associated with Increased diabetes. |
Hypertension | |||
 Galling 2016 [32] | Hypertension (not defined) | SMD/RR (not defined): 0.97, 95%CI 0.32 to 2.98, p = 0.97 | No conclusions drawn. Data indicate no difference between AP monotherapy and APP with D2 antagonists |